danrempel

World-renowned researchers, world-class facilities, and the close cooperation with Israel’s leading pharmaceutical companies and hospitals give the Hebrew University of Jerusalem, the Technology Transfer University, an edge in the development of innovative drug delivery solutions.

Novel drug delivery solutions come about as the result of research into many different Technology Transfer Services areas and fields, including liposomes, polymers, controlled release and encapsulation technologies, and microparticulate and nanoparticulate targeting systems. At the Hebrew University, research into groundbreaking drug delivery systems is underway by some of the world’s acknowledged experts in a number of different fields.

In the School of Pharmacy

• Professor Abraham Domb is an expert in degradable polymers, nanoparticles, and biomaterials

• Professor Elka Touitou leads research in the enhanced delivery of peptides and other drugs through biological membranes

• Professor Simon Benita is a specialist in microparticulate and nanoparticulate targetable drug delivery systems.

At the Casali Institute of Applied Chemistry

• Professor Shlomo Magdassi is an expert in formulation chemistry, nanotechnology, surfactants, dispersion systems, microparticles, and microcapsules.

In the Department of Organic Chemistry

• Professor Chaim Gilon specializes in medicinal chemistry and synthetic chemistry

And at the Institute of Biochemistry, Food Science and Nutrition of the Faculty of Agricultural, Food and Environmental Quality Sciences

• Professor Amos Nussinovitch specializes in the theoretical and practical aspects of hydrocolloids, including: coating of cells, hydrocolloid glues, hydrocolloid cellular solids and water-soluble polymer uses.

Drug Delivery Successes

The Hebrew University has achieved several significant successes in this truly cutting-edge field.

• Doxil (Doxorubicin HCI liposome injection), Alza’s lead product for oncology, was developed by Professor Yechezkel Barenholz of the Faculty of Medicine. It resulted in $375 million in sales in 2006.

• Professor Barenholz also co-founded NasVax Ltd. to develop intranasal delivery systems based on platform technology developed together with Professor Eli Kedar of the Hadassah Medical School. The company’s intranasal delivery system for the influenza vaccine sped from bench to clinical trials in less than 18 months. Within one year of operations, NasVax completed two private investment rounds and had a successful IPO on the Tel Aviv Stock Exchange (TASE). The company is traded under the symbol NSVX.

• Novagali Ltd. was founded to develop solutions for ophthalmology. Based on technology developed by Professor Simon Benita, Novagali’s pipeline includes major products at various stages of development for dry eye, allergy, glaucoma, retinopathies, and more. To date, Novagali has succeeded in raising

You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.